In silico Study of Pharmacological Treatments against SARS-CoV2 Main Protease

In silico Study of Pharmacological Treatments against SARS-CoV2 Main Protease

Youness Kadil, Mohamed Mouhcine, Houda Filali

The COVID-19 caused by a new type of coronavirus has emerged from China and led to thousands ofdeath globally. Despite the efforts engaged in studying this newly emerged virus and searching for itstreatment, the understanding of the COVID-19 drug and target protein interactions still represent a keychallenge. Several molecules have demonstrated In-Vitro activity against the SARS-CoV-2 virus and/or potential clinical benefit in observational and non-randomized studies. Randomized clinical trialsof an appropriate size are currently ongoing to establish the efficacy of these therapeutic proposals.Herein, concerning these diverse guidelines and therapeutic suggestions of different approaches to thetreatment, this research aims to provide a molecular analysis of the interaction between the principalmolecules cited in bibliography and the active protease site of the virus.

2020

protease, docking, pharmacological treatment, SARS-CoV-2, COVID-19

DOI: 10.22207/JPAM.14.SPL1.45

Journal of Pure and Applied Microbiology

Journal of Pure and Applied Microbiology

Microbiology